These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27226502)

  • 21. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
    Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
    Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
    [No Abstract]   [Full Text] [Related]  

  • 23. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
    Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
    Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of targeted therapy for melanoma in the immunotherapy era.
    Sullivan RJ
    Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma, version 2.2013: featured updates to the NCCN guidelines.
    Coit DG; Andtbacka R; Anker CJ; Bichakjian CK; Carson WE; Daud A; Dimaio D; Fleming MD; Guild V; Halpern AC; Hodi FS; Kelley MC; Khushalani NI; Kudchadkar RR; Lange JR; Lind A; Martini MC; Olszanski AJ; Pruitt SK; Ross MI; Swetter SM; Tanabe KK; Thompson JA; Trisal V; Urist MM; McMillian N; Ho M;
    J Natl Compr Canc Netw; 2013 Apr; 11(4):395-407. PubMed ID: 23584343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.
    Testori AAE; Ribero S; Indini A; Mandalà M
    Am J Clin Dermatol; 2019 Dec; 20(6):817-827. PubMed ID: 31177507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.
    Wang H; Tran TT; Duong KT; Nguyen T; Le UM
    Mol Pharm; 2022 Dec; 19(12):4487-4505. PubMed ID: 36305753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
    Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Hashimoto A; Aiba S
    J Dermatol; 2019 May; 46(5):449-452. PubMed ID: 30908705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma.
    Berrocal A; Espinosa E; Marín S; Malvehy J; Moreno D; Lozano MD; Martin-Algarra S; Lopez JA; Conill C; Rodriguez-Peralto JL
    Eur J Dermatol; 2015; 25(5):392-403. PubMed ID: 26693633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
    Tran KA; Cheng MY; Mitra A; Ogawa H; Shi VY; Olney LP; Kloxin AM; Maverakis E
    Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.
    Sierra-Davidson K; Boland GM
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):953-971. PubMed ID: 39060118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.